1Reisman Y, Gips CH, Lavelle SM, Wilson JHP. Clinical presentation of (subclinical) jaundice. The Euricterus project in the Netherlands. Hepato-Gastroenterology 1996 ; 43 : 1190-5.
2Maffei M et Hadengue A. Cholestase de l’adulte : démarche diagnostique. Rev Med Suisse 2006 ; 2 : 1960-4.
3 Bronstein JA, Caumes JL, Richecoeur M, et al. Conduite à tenir devant une cholestase. EMC-Hépatologie 2004 : 113-121.
4 Moon JH, Cho YD, Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis : Comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol 2005 ; 100 : 1051-7.
5Ferrari FS, Fantozzi F, Tasciotti L, et al. A comparative study in 131 patients with suspected biliary obstruction. Med Sci Monit 2005 : MT8-18.
6Rösch T, Meining A, Frühmorgen S, et al. A prospective comparison of the diagnostic accurancy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest Endosc 2002 ; 55 : 870-6.
7 Zandrino F, Curone P, Benzi L, et al. MR versus multislice CT cholangiography in evaluating patients with obstruction of the biliary tract. Abdom Imaging 2005 : 30 ; 77-85.
8Zandrino F, Benzi L, Ferretti ML, et al. Multislice CTcholangiographywithout biliary contrast agent : technique and preliminary clinical results in the assessment of patients with biliaryobstruction. Eur Radiol 2002 ; 12 : 1155-61.
9Yusuf TE, Bhutani MS. Role of endoscopic ultrasonography in diseases of the extrahépatic biliary system. J Gastroenterol Hepatol 2004 ; 19 : 243-50.
10Verma D, Kapadia A, Eisen GM, et al. EUS vs MRCP for detection of choledocholithiasis. Gastrointest Endosc 2006 ; 64 : 248-54.
11Romagnuolo J, Bardou M, Rahme E et al. Magnetic resonance cholangiopancreatography : A meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003 ; 139 : 547-57.
12Vaishali MD, Agarwal AK, Upadhyaya DN, et al. Magnetic resonance cholangiopancreatography in obstructive jaundice. J Clin Gastroenterol 2004 ; 38 : 887-90.
13Farci P, Alter HJ, Wong D, et al. A long term study of hepatitis C virus replication in non-A non-B hepatitis. N Engl J Med 1991 ; 325 : 98-104.
14Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C : High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003 ; 125 : 80-8.
15Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C : Impact of onset of therapy on sustained virologic response. Gastroenterology 2006 ; 130 : 632-8.
16Broers B, Helbling B, François A, et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005 ; 42 : 323-8.
17Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection : The HEP-NET acute-HCV-II study. Hepatology 2006 ; 43 : 250-6.
18Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C : A randomized trial. Hepatology 2006 ; 43 : 923-31.
19Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006 ; 20 : 1157-61.
20Galan MV, Potts JA, Siverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005 ; 39 : 64-7.
21Holt MP and Ju C. Mechanisms of Drug-induced Liver Injury. AAPS J. 2006 ; 8 : E48-54.
22Lewis JH, Ahmed M, Shobassy A, Palese C. Drug-induced liver disease. Curr Opin Gastroenterol 2006 ; 22 : 223-33.
23Criteria of drug-induced liver disorders. Report of an international Consensus Meeting. J Hepatol 1990 ; 11 : 272-6.
24Nunez M. Hepatotoxicity of antiretrovirals : Incidence, mechanisms and management. J Hepatol 2006 ; 44(1 Suppl) : S132-9.
25Larrey D. Drug-induced liver diseases. J Hepatol 2000 ; 32(Suppl 1) : 77-88.
26Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997 ; 26(Suppl 1) : 47-51.
27Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005 ; 43 : 901-10.
28Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001 ; 135 : 262-8.
29Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971 ; 40 : 159.
30Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973 ; I : 735.
31Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical and histological remission of severe chronic active liver disease : A controlled study of treatments and early prognosis. Gastroenterology 1972 ; 63 : 820.
32Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980 ; 21 : 78-83.
33Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH) : Individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002 ; 36 : 480-7.
34Mathurin P. Corticosteroids for alcoholic hepatitis – what’s next ? J Hepatol 2005 ; 43 : 526-33.
35Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005 ; 41 : 353-8.
36Rimola A, Garcia-Tsao G,Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis : A consensus document. International Ascites Club. J Hepatol 2000 ; 32 : 142-53.
37Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis : Report on the consensus conference of the International Ascites Club. Hepatology 2003 ; 38 : 258-66.
38Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006 ; 55(suppl VI).
39Runyon BA, Montana AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exsudate-transudate concept in the differential diagnosis of ascites. Ann Int Med 1992 ; 117 : 215-20.
40Runyon BA, Amillon MR, Akriviadis EA, et al. Bedside inoculation of blood culture bottles is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol 1990 ; 28 : 2811-2.
41Rimola A, Salmeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis : Results of a prospective, randomized, multicentre study. Hepatology 1995 : 21 : 674-9.
42Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than ampicilline-tobramycine in cirrhosis with severe infections. Hepatology 1985 ; 11 : 153.
43Rimola A, Navasa M, Arroyo V. Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Diagn Microbiol Infect Dis 1995 ; 22 : 141-5.
44Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis : Frequency and predictive factors. Hepatology 1988 ; 8 : 27.
45Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999 ; 341 : 203-9.
47Gines P, Rimola A, Planas R, et al. Norfloxacine prevents spontaneous bacterial peritonitis recurrence in cirrhosis : Results of a double blind placebo-controlled trial. Hepatology 1990 ; 12 : 716-24.
48Poynard T, Calès P, Pasta L, et al. Beta-adrenergic antagonist drugs in in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophagial varices. N Engl J Med 1991 ; 324 : 1532-8.
49Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000 ; 33 : 301-7.
50lauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997 ; 16 : 43-55.
51Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol 1994 ; 21 : 317-25.
52Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004 ; 39 : 841-56.
53Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1988 ; 98 : 146-51.
54Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, Gremy F, Michel H. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy : Results of a meta-analysis. Hepatology 1992 ; 15 : 222-8.
55 McIntyre N, Collins P. The liver in cardiovascular and pulmonary disease. In : Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodès J. editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol 2. Oxford : Oxford University Press ; 1999 : 1671-83.
56Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002 ; 6 : 947.
57Bacq Y. Stéatose hépatique aiguë gravidique. Gastroenterol Clin Biol 1997 ; 21 : 109-15.
58Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005 ; 129 : 894-901.
59Palma J, Reyes H, Ribalta J, Hernández I, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy : A randomized, double-blind study controlled with placebo. J Hepatol 1997 ; 27 : 1022-8.
60Riely, CA. Acute fatty liver of pregnancy. Semin Liver Dis 1987 ; 7 : 47.
61Castro, MA, Fassett, MJ, Reynolds, TB, et al. Reversible peripartum liver failure : A new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J Obstet Gynecol 1999 ; 181 : 389.
62Sibai, BM, Ramadan, MK, Usta, I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993 ; 169 : 1000.
63Nunes, JO, Turner, MA, Fulcher, AS. Abdominal Imaging Features of HELLP Syndrome : A 10-Year Retrospective Review. AJR Am J Roentgenol 2005 ; 185 : 1205.
64Chalasani N, Mel Wilcox C. Etiology, evaluation and outcome of jaundice in patients with acquired immunodeficiency syndrome. Hepatology 1996 ; 23 : 728-33.
65Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000 ; 13 : 83-121.
66Becker SD, Lamont JT. Postoperative Jaundice. Seminars in Liver Disease 1988 ; 8 : 183-90.
67 Sameron JM, Rodès J. Post-operative jaundice. In : Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodès J. editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol 2. Oxford : Oxford University Press ; 1999 : 2023-7.
